drugset / Trial / NCT01843023

Extended Release Naltrexone for Opioid-Dependent Youth

NCT01843023

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare 6-month treatment outcomes for 15-21 year old opioid-dependent youth receiving extended release naltrexone (XR-NTX) v. Treatment as Usual (TAU).

Timeline

Start
2013-06
Primary completion
2018-01-31
Completion
2019-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Buprenorphine Other / unclassified 12 mg
Comparator Buprenorphine Other / unclassified 20 mg
Subject Naltrexone Small molecule 380 mg Intramuscular

Indications